

**TABLE 200: DISCONTINUATION DUE TO ADVERSE EVENT**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-2	1	(6) SOF12 + LDV12	0	109	0%
	1	(10) SOF12 + LDV12 + RBV12	0	111	0%
	1	(7) SOF24 + LDV24	0	109	0%
	1	(11) SOF24 + LDV24 + RBV24	0	111	0%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	95	0%
Bacon et al., 2011 RESPOND2	1	(1) PR48	2	80	3%
		(74) B32 PR36-48 RGT	13	162	8%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	0	77	0%
	1	(10) SOF12 + LDV12 + RBV12	1	78	1%
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	1	79	1%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	0	10	0%
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Forns et al., 2014 PROMISE	1	(1) PR48	0	133	0%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
		(42) SIM12 PR24-48 RGT	1	260	0%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	1	103	1%
Jensen et al., 2015 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	18	398	5%
Kumada et al., 2014	1b	(17) DCV24 + ASU24	2	87	2%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	4	47	9%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
	1	(10) SOF12 + LDV12 + RBV12	0	21	0%
Lawitz et al., 2014 COSMOS	1	(5) SIM12 + SOF12	0	14	0%
		(72) SOF12 + SIM12 + RBV12	0	27	0%
Lawitz et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12(50 mg q.d.)	0	33	0%
		(59) GRZ18 + ELB18(50 mg q.d.)	0	32	0%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	1	32	3%
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	0	33	0%
Lok et al., 2014 DUAL A2	1b	(17) DCV24 + ASU24	0	20	0%
Lok et al., 2014 QUAD B2	1	(18) DCV24 + ASU24 + PR24	0	21	0%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	2	205	1%
Molina et al., 2015 PHOTON-2	3	(4) SOF24 + RBV24	2	49	4%
Osinusi et al., 2014 SYNERGY	1	(6) SOF12 + LDV12	0	14	0%
Pol et al. et al., 2015	1	(40) SOF12 + PR12	0	80	0%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	39	384	10%
		(68) SIM12 PR48	12	379	3%
Sulkowski et al., 2014-3	2+3	(4) SOF24 + RBV24	1	41	2%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	1	51	2%
Zeuzem et al., 2014 SAPPHIRE-II	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	3	297	1%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	4	132	3%
		(39) T12 PR48 q8	17	266	6%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	3	66	5%
		(68) SIM12 PR48	3	66	5%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir. Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.